No Data
Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT
H.C. Wainwright Maintains Metagenomi Technologies, LLC(MGX.US) With Buy Rating, Maintains Target Price $7
Reported Earlier, Metagenomi Shares Data On SMART Gene Editing Platform At AIChE Conference, Emphasizing AAV Packaging
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
Microsoft, BlackRock Plan $30 Billion AI Infrastructure Fund -- Barrons.com
H.C. Wainwright Maintains Metagenomi Technologies, LLC(MGX.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Mitchell Kapoor maintains $Metagenomi Technologies, LLC(MGX.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success
No Data
No Data